Roche's obinutuzumab gets CHMP backing for lupus indication

The EMA's medicines committee has recommended Gazyva/Gazyvaro for moderate-to-severe SLE, backed by Phase III data showing a 23-point response-rate

Roche's obinutuzumab gets CHMP backing for lupus indication

Roche has secured a positive opinion from the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) for obinutuzumab (Gazyva/Gazyvaro) as an add-on treatment for adult patients with moderate-to-severe, active, autoantibody-positive systemic lupus erythematosus (SLE) who have not responded adequately to standard therapy. A formal European Commission decision, which typically follows CHMP recommendations within two to three months, is expected shortly.

The recommendation is based on the Phase III ALLEGORY study, which enrolled approximately 300 patients randomised 1:1 to obinutuzumab plus standard therapy or placebo plus standard therapy for 52 weeks. At the primary endpoint, 76.7% of patients in the obinutuzumab arm achieved at least a four-point improvement in the SLE Responder Index (SRI-4), compared with 53.5% in the placebo arm, an adjusted difference of 23.1 percentage points (95% CI: 12.5–33.6, p<0.001). The drug also met all key secondary endpoints, including BICLA response, sustained glucocorticoid reduction and time to first disease flare. Remission rates, measured by the DORIS standard, more than doubled relative to placebo (33.8% versus 13.8%). No new safety signals were identified.

Regulatory context

The CHMP opinion adds SLE to a growing list of immune-mediated indications for obinutuzumab, which is already approved in more than 65 countries for lupus nephritis and in the US for idiopathic nephrotic syndrome in children and young adults. In the US, the FDA accepted Roche's supplemental Biologics License Application for SLE earlier in 2026, meaning a parallel approval decision is on the horizon in that market. The drug is also being reviewed for primary membranous nephropathy following an FDA filing acceptance.

Levi Garraway, Roche's Chief Medical Officer and Head of Global Product Development, said the CHMP opinion "brings Gazyva/Gazyvaro a step closer to offering people with SLE a new option that may achieve meaningful and sustained disease control."

Market landscape

SLE affects an estimated three million people globally and around 270,000 in Europe, with the prevalence rising. Despite the availability of hydroxychloroquine, mycophenolate mofetil and belimumab (a BAFF inhibitor approved by the EMA in 2011), a substantial proportion of patients experience recurring flares, progressive organ damage and chronic steroid dependence. Approximately half will develop lupus nephritis within five years of diagnosis, raising the stakes for early and effective disease control.

The anti-CD20 class is well established in haematological oncology and rheumatology, with rituximab used off-label in SLE for years. Obinutuzumab's differentiation rests on its glycoengineered Fc region, which Roche says produces higher binding affinity and increased antibody-dependent cellular cytotoxicity compared with Type I anti-CD20 agents. If the European Commission approves the CHMP recommendation, it would be the first approved glycoengineered, Type II anti-CD20 therapy in the SLE indication. That mechanistic distinction may carry weight with clinicians who have seen mixed real-world results with rituximab in this population.

Roche is also investigating mosunetuzumab, a CD20xCD3 bispecific antibody, in SLE with or without active lupus nephritis, signalling a broader bet on B cell depletion strategies across the autoimmune kidney-disease spectrum. Near-term catalysts include the FDA's decision on the sBLA and further data readouts from the ALLEGORY open-label extension, which runs to 104 weeks and will inform durability arguments for payers and guideline committees.